FDA Advisory Committee recommends approval of Jardiance ® (empagliflozin) for cardiovascular indication   in 12-11 vote

Endocrinologic and Metabolic Drugs Advisory Committee votes in favor   of CV mortality benefit for JARDIANCE for adults with type 2 diabetes
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news